Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)

Launched by SOHAG UNIVERSITY · Jun 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well radioactive iodine therapy (called RAI131) works for people with differentiated thyroid cancer, which is a common type of thyroid cancer that usually grows slowly and has a good chance of successful treatment. The trial focuses on patients who have had surgery to remove their thyroid gland and then received RAI treatment to destroy any remaining cancer cells. Researchers want to learn more about the outcomes of this therapy in people who are considered low to intermediate risk after their initial treatment.

People who may be eligible for this study are adults over 18 years old who have been diagnosed with differentiated thyroid cancer and have already had their thyroid removed through surgery, followed by RAI treatment. The trial does not include those with more aggressive types of thyroid cancer, distant spread of the disease, or other cancers. Participants will likely have regular follow-up visits where doctors check for any signs of the cancer returning by doing blood tests and imaging scans. This study aims to help improve care and guide treatment decisions for future patients with similar types of thyroid cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Pathologically or cytologically proven differentiated thyroid cancer.
• • Total thyroidectomy with or without lymph node dissection
• • Patient was treated by RAI after surgery
• • Male and female patients
• • Age \>18 yrs
• Exclusion Criteria:
• • 1) Patients with undifferentiated thyroid cancer. 2) patients with high risk (distant metastasis) 3)patient with double malignancy 4) medullary thyroid cancer 4) Patient age \< 18 years. 5)patient not treated by surgery or RAI